ASX-listed MGC Pharmaceuticals march towards full commercialisation of its cannabis-based dermatological skin care line is a step closer with the company announcing the start of human clinical trials of its products. The company says it plans to commence sales of its unique derma skin care range that will target acne amongst other things from September.
26/01/2017 - 07:11
MGC to test cannabis skin care product in human trials
By Matt Birney
26/01/2017 - 07:11
Related Data & Insights
-
-
Rank Company Revenue th Argent BioPharma $1.7m 201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
01 Dec 2023
Board Moves December 1, 2023
28 Jul 2023
Board Moves July 28, 2023
30 Jun 2023
MGC Pharma sacks senior staffer
07 Jun 2023
Board Moves May 31 to June 2, 2023
01 Mar 2023
Board Moves March 1, 2023
03 Jan 2023
Board Moves January 3, 2023
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX